Pfizer (PFE) Inventory Average (2009 - 2026)

Pfizer has disclosed Inventory Average across 18 years of filings, most recently posting $10.7 billion for Q1 2026.

• In Q1 2026, Inventory Average fell 1.76% year-over-year to $10.7 billion; the TTM figure through Mar 2026 stood at $10.7 billion (down 1.76% YoY), while the FY2025 annual figure was $10.8 billion, down 4.73% from the prior year.
• Inventory Average eased to $10.7 billion in Q1 2026, from $11.1 billion in the prior quarter.
• Over the last five years, Inventory Average for PFE reached as high as $11.6 billion in Q3 2024 and fell as low as $9.2 billion in Q4 2022.
• The 5-year median for Inventory Average is $10.5 billion (2024), against an average of $10.5 billion.
• Annual changes were most pronounced in 2022 — Inventory Average increased 17.15% — and 2023, when it slipped 2.85%.
• A 5-year view of Inventory Average shows it stood at $9.2 billion in 2022, then increased by 10.27% to $10.2 billion in 2023, then increased by 10.69% to $11.3 billion in 2024, then declined by 1.99% to $11.1 billion in 2025, then dropped by 3.62% to $10.7 billion in 2026.
• According to Business Quant data, Inventory Average over the past three periods registered $10.7 billion, $11.1 billion, and $11.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.